Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, New York 14642


Purpose:

The purpose of this study is to determine if omega-3 fatty acids enhance the antiplatelet effects of aspirin.


Study summary:

Although aspirin has been a stalwart treatment in the prevention and treatment of myocardial infarction and stroke, it does not have its expected effects in a significant proportion of the population. This phenomenon has been termed "aspirin resistance". Omega-3 fatty acid supplementation has been associated with a reduced risk of sudden cardiac death and myocardial infarction. The beneficial effects of omega-3s are considered to be partially due to their ability to prevent platelet aggregation. However, the ability of omega-3s to enhance the effects of aspirin in those who suffer from aspirin resistance has not been determined. It is known that aspirin stimulates the production of potent lipid mediators from omega-3 fatty acids and that these mediators have powerful antiinflammatory and tissue-protective effects. Thus, the treatment of individuals at high risk for myocardial infarction and stroke with both aspirin and a pharmaceutical-grade omega-3 fatty acid medication may be a powerful combination in the prevention and treatment of life-threatening cardiovascular disease.


Criteria:

Inclusion Criteria: - Willing to participate by providing informed consent and committing to complete the study. This includes adhering to the study diet. - No chronic disease by history and based on a complete blood count and comprehensive metabolic profile. - Commitment to not taking aspirin, non-steroidal anti-inflammatory medications, and to limit fish intake to ≤2 meals during the 7 days prior to each CRC study period. They will also need to abstain from taking a list of over-the-counter medications that include aspirin. For the duration of the study, they will also be asked to abstain from taking fish and flax seed oil supplements. Exclusion Criteria: - Reports the presence of chronic disease (e.g. cardiovascular, renal, hepatic, neurodegenerative, neoplastic, metabolic {diabetes}, hypertension). - Reports taking a systemic medication chronically. - History of serious adverse reaction or allergy to aspirin or fish oil. - Baseline platelet count <100 000 or >500 000, hematocrit <30%, or white blood cell count >20 000. - Any abnormality from a screening CBC and complete blood count that suggests acute or chronic disease. - Nicotine user. - History of alcohol abuse - Pregnancy by history or urine/serum pregnancy test - History of intestinal malabsorption syndrome including gastric bypass surgery


NCT ID:

NCT00771914


Primary Contact:

Principal Investigator
Robert C Block, MD, MPH
University of Rochester School of Medicine and Dentistry


Backup Contact:

N/A


Location Contact:

Rochester, New York 14642
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.